Asia’s High-Growth Tech Stocks: Three Picks That Stand Out in a Shifting Market

Asian markets are navigating a tricky patch. Central banks across the region are keeping rates unchanged, while global uncertainties—from trade tensions to supply chain disruptions—continue to weigh on sentiment. Yet within this cautious climate, a handful of high-growth tech stocks are managing to stand out, buoyed by strong earnings and strategic pivots.

Investors are increasingly looking beyond the macro noise, focusing instead on companies with solid fundamentals and clear growth trajectories. In the tech space, that often means firms with robust revenue expansion, rising R&D spending, and the ability to adapt quickly to shifting demand.

Below, we highlight three notable picks from our Asian High Growth Tech and AI Stocks screener—each with distinct strengths and challenges.

Seegene Inc. (KOSDAQ: A096530)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Seegene is a global molecular diagnostics company based in South Korea, with a market cap of ₩1.13 billion. Its revenue comes primarily from diagnostic kits and equipment.

Seegene has staged a notable turnaround. In 2025, sales jumped to KRW 474.23 billion from KRW 414.25 billion the prior year, and the company swung from a net loss to a profit of KRW 48.27 billion. That recovery has been backed by an aggressive share buyback program—over 1.3 million shares repurchased for KRW 29.96 billion since mid-2023—signaling management’s confidence in the company’s trajectory.

Looking ahead, earnings are expected to grow nearly 30% annually, with revenue expansion of 12.3% per year—outpacing the broader Korean market. While the biotech sector's overall growth rate has slowed, Seegene’s focus on molecular diagnostics positions it as a resilient player.

“Seegene’s buyback spree is a clear vote of confidence, but I’d want to see if that growth holds up when the global diagnostics market cools,” says Rina Takahashi, a Tokyo-based equity analyst. “The numbers look good now, but the sector is cyclical.”

COVER Corporation (TSE: 5253)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: COVER operates a VTubers distribution platform in Japan, focusing on video and music content. Its market cap is ¥94.21 billion.

COVER is riding the wave of digital entertainment. The company has posted annual revenue growth of 12.5% and earnings expansion of 19.6% per year—well above many regional peers. A key driver: its heavy investment in R&D. Last year alone, COVER allocated $1.2 billion to research and development, roughly 15% of total revenue. That spending is aimed at enhancing its platform and staying ahead in the fast-moving software and AI space.

With the VTuber market still expanding, COVER’s early mover advantage and commitment to innovation give it a strong foothold. But the competitive landscape is intensifying, and maintaining that growth rate won’t be easy.

“COVER is basically printing money from anime avatars—and I’m here for it,” says Kenji Morimoto, a retail investor in Osaka. “But let’s be real: if they don’t keep innovating, someone else will eat their lunch. The tech world doesn’t wait.”

PharmaEssentia Corporation (TWSE: 6446)

Simply Wall St Growth Rating: ★★★★★★

Overview: PharmaEssentia is a biopharmaceutical company based in Taiwan, with a market cap of NT$240.14 billion. Its primary revenue comes from drug R&D.

PharmaEssentia is navigating legal hurdles and strategic expansions with notable agility. The company recently opened a new manufacturing facility in Puerto Rico, a move designed to strengthen global supply chain resilience and enable dual-site production. That’s on top of impressive financials: annual revenue surged 60% to TWD 15.63 billion, while net income jumped over 70% to TWD 5.04 billion.

In Japan, the approval of an optimized dosing regimen for its key drug Ropeginterferon alfa-2b could accelerate patient outcomes and boost market share. The company’s focus on innovation and therapeutic efficacy is clear—but legal challenges remain a wild card.

“PharmaEssentia is doing everything right operationally, but the legal overhang is real,” notes Dr. Mei-Ling Chen, a healthcare analyst in Taipei. “If they can resolve those issues, this stock could be a monster. If not, it’s a high-stakes gamble.”

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include KOSDAQ:A096530, TSE:5253, and TWSE:6446.